Box-Behnken optimization design and enhanced oral bioavailability of thymopentin-loaded poly (butyl cyanoacrylate) nanoparticles

Pharmazie

Volumn 66, Issue 5, 2011, Pages 339-347

  Jin, Xuefeng ^a   Huang, Aiwen ^a   Ping, Qineng ^a   Cao, Feng ^a   Su, Zhigui ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYANOACRYLATE DERIVATIVE; DEXTRAN; ENBUCRILATE; NANOPARTICLE; POLOXAMER; POLY(BUTYL CYANOACRYLATE); SODIUM METABISULFITE; THYMOPENTIN; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOX BEHNKEN OPTIMIZATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; INFRARED SPECTROSCOPY; NANOEMULSION; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; POLYMERIZATION; PROCESS OPTIMIZATION; RAT; T LYMPHOCYTE SUBPOPULATION; TRANSMISSION ELECTRON MICROSCOPY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CYANOACRYLATES; CYCLOPHOSPHAMIDE; DRUG CARRIERS; DRUG DESIGN; ELECTROCHEMISTRY; FEMALE; FLOW CYTOMETRY; HYDROLYSIS; IMMUNITY; IMMUNOSUPPRESSIVE AGENTS; KINETICS; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; T-LYMPHOCYTE SUBSETS; THYMOPENTIN;

EID: 79957641778     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0307     Document Type: Article

References (39)

1. Avery BS, Ord RA (1982) The use of butyl cyanoacrylate as a tissue adhesive in maxillo-facial and cranio-facial surgery. Br J Oral Surg 20: 84-95. (Pubitemid 12045602)
2. Behan N, Birkinshaw C (2001) Preparation of poly(butyl cyanoacrylate) nanoparticles by aqueous dispersion polymerisation in the presence of insulin. Macromol Rapid Comm 22: 41-43. (Pubitemid 33225335)
3. Birkinshaw C, Pepper DC (1986). The thermal degradation of polymers of n-butylcyanoacrylate prepared using tertiary phosphine and amine initiators. Polym Degrad Stab, 16:241-59.
4. Bootz A, Vogel V, Schubert D, Kreuter J (2004) Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 57: 369-375. (Pubitemid 38283717)
5. Chi Q, Xie X, Zhang J, Yang Y, Li Z, Mei X (2008) Synthesis, characterization and biological activities of thymopentin ethyl ester. Pharmazie, 63 (11): 784-787.
6. Des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116: 1-27. (Pubitemid 44792295)
7. Desai MP, Labhasetwar V, Amidon GL, Levy RJ (1996) Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 13 (12): 1838-1845. (Pubitemid 27034116)
8. Doi T, Nagai H, Tsukuda R, Suzuki T (1996) Dose-response relationships of cytotoxicity, PFC response and histology in the spleen in rats treated with alkylating agents. Toxicology 107: 47-60.
9. Douglas SJ, Ilium L, Davis SS (1985) Particle size and size distribution of poly(butyl 2-cyanoacrylate) nanoparticles. II: Influence of stabilizers. J Colloid Interface Sci 103: 154-163. (Pubitemid 15437410)
10. Fen Xia Hou HFY, Tao Yu, Wei Chen, (2007) The immunosuppressive effects of 10 mg/kg cyclophosphamide in Wistar rats. Environ Toxicol Pharmacol 24: 30-36.
11. Gao J, Ding X, Chu C, Lu L, Zhang Y, Chen Y, Fan W, Li G, Gao S (2009) Dry powder inhalations containing thymopentin and its immunomodulating effects in Wistar rats. Eur J Pharm Sci 36: 572-579.
12. Goldstein G, Audhya TK (1985) Thymopoietin to thymopentin: experimental studies. Surv Immunol Res 4 Suppl 1: 1-10. (Pubitemid 16231850)
13. Goldstein G, Scheid MP, Boyse EA, Schlesinger DH, Van Wauwe J, (1979)A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science 204: 1309-1310. (Pubitemid 9223717)
14. Graf A, MacDowell A, Rades T (2009) Poly(alkylcyanoacrylate) nanoparticles for enhanced delivery of therapeutics - is there real potential? Expert Opin Drug Deliv 6: 371-387.
15. Heavner GA, Kroon DJ, Audhya T, Goldstein G (1986) Biologically active analogs of thymopentin with enhanced enzymatic stability. Peptides 7: 1015-1019. (Pubitemid 17226728)
16. Heizmann J, Langguth P, Biber A, Oschmann R, Merkle HP, Wolffram S (1996) Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes. Peptides 17:1083-1089. (Pubitemid 26419731)
17. Jani P, Halbert GW, Langridge J, Florence AT (1990) Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 42: 821-826.
18. Leahey AB, Gottsch JD, Stark WJ (1993) Clinical experience with N-butyl cyanoacrylate (Nexacryl) tissue adhesive. Ophthalmology 100: 173-180. (Pubitemid 23056528)
19. Lescure F, Zimmer Z, Roy D, Couvreur P (1992) Optimization of polyalkyl-cyanoacrylate nanoparticle preparation: Influence of sulfur dioxide and pH on nanoparticle characteristics. J Colloid Interface Sci 154: 77-86.
20. Li LQ, Wang JX, Song DM, Fan SG, Mei L (1996) Building up of an animal model of conditioned immunosuppression and analysis of its possible mechanism. Yao Xue Xue Bao 31: 477-480. (Pubitemid 126432105)
21. Liang Yong-tao XZ-b, Wang Ming-zhe, Zhao Shuang, Wang En-si (2008). Spectral Data Analysis and Identifi cation of Thymopentin. Chin J Pharm 39: 120-122.
22. Lowe PJ, Temple CS (1994) Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J Pharm Pharmacol 46: 547-552. (Pubitemid 24213278)
23. Morel S, Ugazio E, Cavalli R, Gasco MR (1996) Thymopentin in solid lipid nanoparticles. Int J Pharm 132: 259-261. (Pubitemid 26158724)
24. Mulik R, Mahadik K, Paradkar A (2009) Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: Physicochemical characterization and stability study. Eur J Pharm Sci 37: 395-404.
25. Muruganandan S, Lal J, Gupta PK (2005) Immunotherapeutic effects of mangiferin mediated by the inhibition of oxidative stress to activated lymphocytes, neutrophils and macrophages. Toxicology 215: 57-68. (Pubitemid 41423653)
26. Panico A, Pignatello R, Cardile V, Puglisi G (1997) Preparation of liposome formulations containing immunomodulatory peptides. Pharm Acta Helv 72: 1-10. (Pubitemid 27089537)
27. Pignatello R, Pecora TM (2007) Conjugation of thymopentin (TP5) with lipoamino acid residues increases the hydrolytic stability and preserves the biological activity. Pharmazie 62: 663-667. (Pubitemid 47507838)
28. Schroeder U, Sommerfeld P, Sabel BA (1998) Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier. Peptides 19: 777-780. (Pubitemid 28255016)
29. Simeonova M, Ivanova G, Enchev V, Markova N, Kamburov M, Petkov C, Devery A, O'Connor R, Brougham D (2009) Physicochemical characterization and in vitro behavior of daunorubicin-loaded poly(butylcyanoacrylate) nanoparticles. Acta Biomater 5: 2109-2121.
30. Singh VK, Biswas S, Mathur KB, Haq W, Garg SK, Agarwal SS (1998) Thymopentin and splenopentin as immunomodulators. Current status. Immunol Res 17: 345-368.
31. Sullivan CO, Birkinshaw C (2004) in vitro degradation of insulin-loaded poly (n-butylcyanoacrylate) nanoparticles. Biomaterials 25: 4375-4382.
32. Sun DL PZS, Wang YF, Chen HP, Wu HG, Zhai DD (2000) Effect of medicinal vesiculation on hematopoeisis function of rats treated by cyclophosphamide chemotherapy. Zhe Jiang Zhong Yi Xue Yuan Xue Bao 24:74-78.
33. Tischio JP, Patrick JE, Weintraub HS, Chasin M, Goldstein G (1979) Short in vitro half-life of thymopoietin 32-36 pentapeptide in human plasma. Int J Pept Protein Res 14: 479-484.
34. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P (2003) Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 55: 519-548. (Pubitemid 36423302)
35. Wang J, Lu WL, Liang GW, Wu KC, Zhang CG, Zhang X, Wang JC, Zhang H, Wang XQ, Zhang W (2006) Pharmacokinetics, toxicity of nasal cilia and immunomodulating effects in Sprague-Dawley rats following intranasal delivery of thymopentin with or without absorption enhancers. Peptides 27: 826-835.
36. Xin Li LZ, Yonghui Chang, Shubao Shen, Hanjie Ying, Pingkai Ouyang (2007) Kinetics of adsorption of thymopentin on a gel-type strong cation-exchange resin. Chromatogr Sci Ser 66: 231-235.
37. Yin Y, Chen D, Qiao M, Lu Z, Hu H (2006) Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J Control Release 116: 337-345. (Pubitemid 44827411)
38. Zheng Ai-ping LM-g, Wang Jian-cheng, Zhang Qiang., (2007) Study on preparation release in vitro and biological activity of thymopentin-loaded pH-sensitive chitosan nanoparticles for oral administration. Chin Pharm J 42: 679-685.
39. Zheng AP, Wang JC, Lu WL, Zhang X, Zhang H, Wang XQ, Zhang Q (2006) Thymopentin-loaded pH-sensitive chitosan nanoparticles for oral administration: preparation, characterization, and pharmacodynamics. J Nanosci Nanotechnol 6: 2936-2944. (Pubitemid 44579965)